Aurobindo Pharma Gets USFDA Approval for First MDI Respiratory Product
Aurobindo Pharma Limited has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Beclomethasone Dipropionate HFA Inhalation Aerosol in 40 mcg and 80 mcg strengths.
The approval marks an important step in Aurobindo Pharma’s expansion into complex respiratory therapies and represents the company’s first metered-dose inhaler (MDI) product.
The product is a generic equivalent of QVAR® Inhalation Aerosol 40 mcg and 80 mcg, marketed by Teva Branded Pharmaceutical Products R&D LLC.
Aurobindo Pharma Enters MDI Segment
The newly approved Beclomethasone Dipropionate HFA Inhalation Aerosol will be manufactured at Aurobindo Pharma’s Raleigh facility in North Carolina, which is owned by its wholly owned step-down subsidiary Aurolife Pharma LLC.
The company expects to launch the product in the upcoming quarters.
Aurobindo said the approval expands its capabilities in the inhalation segment and supports its strategy of moving beyond conventional generics into more complex and differentiated therapies.
US Market Opportunity Estimated at $301 Million
According to IQVIA data cited by Aurobindo Pharma, the US market for the approved product and newer versions of the reference product, QVAR® RediHaler, was estimated at approximately US$301 million for the 12 months ended July 2026.
The market opportunity provides a potential avenue for Aurobindo to build a presence in the US respiratory segment following the approval.
However, the reported market size should not be interpreted as Aurobindo Pharma’s expected revenue from the product. Actual sales will depend on the launch timing, pricing, competition, market share, and other commercial factors.
First MDI Product Marks Strategic Expansion
The approval is particularly significant because it represents Aurobindo Pharma’s first metered-dose inhaler product.
The company said it is expanding into complex inhalation therapies as part of its strategy to create another avenue for differentiated growth in the US market.
Respiratory products can involve additional manufacturing and development complexities compared with conventional oral solid dosage generics, making the approval strategically relevant to Aurobindo’s portfolio expansion.
Product Indicated for Asthma Treatment
Beclomethasone Dipropionate HFA Inhalation Aerosol is indicated for the maintenance treatment of asthma as prophylactic therapy in patients aged 5 years and older.
It is also indicated for asthma patients who require systemic corticosteroid administration, where adding Beclomethasone Dipropionate HFA Inhalation Aerosol may reduce or eliminate the need for systemic corticosteroids.
Aurobindo’s USFDA Approvals Reach 596
With this approval, Aurobindo Pharma’s cumulative USFDA ANDA approvals have reached 596.
These include:
- 571 final approvals
- 25 tentative approvals
The company said the latest approval further strengthens its portfolio of complex and differentiated products.
Focus Shifts Towards Complex Generics
Aurobindo Pharma has traditionally built a significant presence in generic pharmaceuticals, active pharmaceutical ingredients, and other healthcare products.
The latest approval indicates a continued push toward complex products and differentiated therapies, particularly in the US market.
The company said its expansion into complex inhalation therapies is intended to create the next phase of differentiated growth.
What Investors Should Watch
For investors, the key developments to monitor following the USFDA approval will be:
- Commercial launch timing
- Initial prescription and market uptake
- Pricing and competitive intensity
- Market share captured by the generic product
- Revenue contribution from the inhalation portfolio
- Further approvals for complex respiratory products
- Expansion of Aurobindo’s differentiated US product portfolio
The $301 million market estimate provides an indication of the addressable market, but the actual financial contribution to Aurobindo will depend on commercial execution.
Investor Takeaway
Aurobindo Pharma’s latest USFDA approval is more significant than a routine ANDA approval because it marks the company’s entry into metered-dose inhalers and complex respiratory therapies.
The approved Beclomethasone Dipropionate HFA Inhalation Aerosol has an estimated US market opportunity of $301 million, according to IQVIA data cited by the company, and is expected to launch in the coming quarters.
With cumulative USFDA ANDA approvals now at 596, Aurobindo continues to expand its US generic portfolio while moving into more complex and differentiated products.
For investors, the next important trigger will be commercial launch and the product’s eventual revenue and margin contribution, rather than regulatory approval alone.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should independently evaluate Aurobindo Pharma’s financial performance, valuation, product pipeline, regulatory risks, competitive environment, and prospects before making any investment decision.